BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20506021)

  • 1. Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
    Puig N; Caballero MD; Alcoceba M; Sebastián E; Balanzategui A; Sarasquete ME; García-Sanz R; González-Díaz M
    Ann Hematol; 2011 Feb; 90(2):227-9. PubMed ID: 20506021
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma.
    de Lavallade H; Mohty M; El-Cheikh J; Cassier PA; Faucher C; Fürst S; Vey N; Stoppa AM; Sainty D; Arnoulet C; Xerri L; Gastaut JA; Blaise D; Bouabdallah R
    Br J Haematol; 2006 Nov; 135(3):408-10. PubMed ID: 16978221
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapsed diffuse large B-cell lymphoma treated by reduced-intensity allogeneic stem cell transplantation with donor lymphocyte infusion.
    Chaudhry QU; Ahmed P; Ullah K; Satti TM; Raza S; Mehmood SK; Akram M; Ahmed S
    J Coll Physicians Surg Pak; 2010 Mar; 20(3):211-3. PubMed ID: 20392389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.
    Ho AY; Devereux S; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2003 Apr; 31(7):551-7. PubMed ID: 12692620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
    Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
    Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation in follicular lymphoma.
    Khouri IF
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular lymphoma: emerging therapeutic strategies.
    Kenkre VP; Kahl BS
    Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation.
    Yamamoto R; Takaori-Kondo A; Kanda J; Imada K; Ichinohe T; Ishikawa T; Ohmori K; Uchiyama T
    Bone Marrow Transplant; 2008 Mar; 41(6):591-3. PubMed ID: 18071292
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
    Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
    Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT.
    Uehara T; Nakaseko C; Yokota A; Saito Y; Nishimura M
    Am J Hematol; 2002 Sep; 71(1):37-40. PubMed ID: 12221672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma.
    Forrest DL; Thompson K; Nevill TJ; Couban S; Fernandez LA
    Bone Marrow Transplant; 2002 Jun; 29(12):973-8. PubMed ID: 12098065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
    Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
    Mohty M; Labopin M; Tabrizzi R; Theorin N; Fauser AA; Rambaldi A; Maertens J; Slavin S; Majolino I; Nagler A; Blaise D; Rocha V; ;
    Haematologica; 2008 Feb; 93(2):303-6. PubMed ID: 18245655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
    Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.